- Home
- ICCM vs LITS Comparison
ICCM vs LITS Comparison
Compare ICCM & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | LITS |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | Israel | United States |
| Employees | N/A | 4 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4M | 40.8M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICCM | LITS |
|---|---|---|
| Price | $0.62 | $1.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 251.7K | ★ 283.6K |
| Earning Date | 03-17-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $53.39 | N/A |
| Revenue Next Year | $487.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.95 |
| 52 Week High | $1.40 | $3.03 |
Technical Indicators
Market Signals| Indicator | ICCM | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 48.35 |
| Support Level | $0.58 | $0.98 |
| Resistance Level | $0.62 | $1.65 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 26.34 | 47.67 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.